In 1977 Ceriani et al. described the production of a polyclonal antiserum against defatted human cream, and its immunocytochemical reactivity with mammary epithelial cells. Subsequently a rabbit antiserum was raised against this antigen (Heyderman et al., 1979) and was shown to react with both normal and neoplastic mammary epithelium in histological sections. It was noted that reactivity with this antiserum was most marked on the luminal aspect of mammary epithelial cells. The antiserum also reacted with many different normal glandular epithelia and with adenocarcinomas from a wide variety of sites including stomach, prostate, uterus, ovary, lung, pleura and thyroid.
The antigen detected by this antiserum was designated 'epithelial membrane antigen' (EMA) by Heyderman et al. (1979) and subsequent studies proved its value in the detection of breast carcinoma metastases in histological sections of liver, lymph nodes and bone marrow (Sloane et al., 1980; and in marrow smears . Anti-EMA antiserum was also shown to be useful for differentiating anaplastic carcinoma from malignant lymphomas and for the recognition of spindle cell epithelial malignancies . More recently it has been reported that the antiserum may be used to detect neoplastic cells in serous effusions and also in bone marrow smears in which they cannot be identified by routine haematological examination (Dearnaley et al., 1983; Redding et al., 1983) .
In addition to these studies of direct relevance to pathological diagnosis, the distribution of EMA has been documented in fetal and adult tissues and its expression on disordered squamous epithelium reported (Sloane et al., 1982) .
Epithelial membrane antigen has recently been purified from human milk and shown to be markedly heterogeneous in nature, covering a wide range of mol. wts. This suggests that polyclonal antisera raised against the antigen will contain antibodies directed against multiple different determinants on the immunising material. This fact, together with the difficulty inherent in obtaining large amounts of polyclonal anti-EMA antisera of reproducible quality, has prompted us to raise monoclonal antibodies of this specificity. In the present paper two such monoclonal antibodies are described, together with details of their reactions against the antigen used for immunisation, as analysed by immunoblotting. One of these antibodies has been extensively tested against normal and neoplastic human tissues and shown to be a valuable reagent for the detection of tumour metastases and the diagnosis of anaplastic carcinoma.
A comparison of its reactions with those of polyclonal anti-EMA antibodies and another monoclonal anti-EMA antibody is presented in an accompanying paper (Heyderman et al., 1985) .
Materials and methods
Preparation of antigen Epithelial membrane antigen was prepared from human milk as described elsewhere (Heyderman et al., 1985) .
Antibodies and immunohistological reagents Rabbit anti-mouse Ig and peroxidase conjugated antibodies against mouse Ig and rabbit Ig were obtained from Dakopatts a/s. Complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes) were prepared as described previously (Cordell et al., 1984) .
Production of monoclonal antibody Balb/c mice were immunised with 50 ug of EMA antigen emulsified in Freund's complete adjuvant on 4 occasions at 10 day intervals. One of the mice was then given an i.v. injection of 100 pg of antigen and sacrificed 3 days later. The spleen was removed aseptically, a cell suspension prepared and fusion with NS I myeloma cells performed as described previously (Mason et al., 1983) . Following 8 days culture, supernatants were removed and tested for activity by immunoperoxidase staining on cryostat sections of a ductal carcinoma of breast.
Immunoenzymatic labelling techniques
Immunoperoxidase staining Staining was performed by a two-or three-stage procedure as described previously (Gatter et al., 1984a) . In brief, acetone fixed cryostat sections or de-waxed paraffin sections were incubated in sequence with monoclonal antibody and with peroxidase-conjugated rabbit anti-mouse Ig. In the two-stage method the peroxidase reaction was then revealed by incubation with diaminzobenzidine/H202 substrate. In the three-stage technique an additional incubation with peroxidase-conjugated swine anti-rabbit Ig was performed prior to development of the peroxidase reaction.
Immuno-alkaline phosphatase labelling This was performed as described previously using the unlabelled antibody APAAP technique (Cordell et al., 1984) or by a two-stage indirect immuno-alkaline phosphatase procedure. In the latter technique incubation with monoclonal antibody was followed by alkaline phosphatase-conjugated rabbit antimouse Ig (kindly provided by Dr K.J. Pluzek). In both procedures the enzyme label was revealed by incubation with a substrate containing naphthol AS-MX and either Fast Red or hexazotised New Fuchsin (Cordell et al., 1984) . (Laemmli, 1970) , 20pg
of antigen being applied to each track. The separated constituents of the antigen were then transferred electrophoretically to nitrocellulose membrane in a Bio-Rad Trans-Blot cell, according to the method of Towbin et al. (1979) . The membrane was then incubated in turn with monoclonal antibody, unlabelled sheep anti-mouse Ig and APAAP complexes, as described previously (Cordell et al., 1984) . The alkaline phosphatase reaction was then developed using naphthol AS-MX phosphate and Fast Red as substrate (Cordell et al., 1984) . (Figure 7 ). In addition the antibody was shown to react strongly with neoplastic plasma cells from a case of multiple myeloma.
Discussion
It is evident from the results reported above that the immunocytochemical reactions of antibody E29 are closely similar to those obtained with the polyclonal antiserum anti-EMA (Heyderman et al., 1979; Sloane et al., 1982) . In particular it is of interest that the antibody shows a broad spectrum of reactivity against human epithelial cells, despite its having been raised against an extract of human milk. In keeping with previous studies of polyclonal anti-EMA the monoclonal reagent was unreactive with normal 2 40,000-190,000--- Figure 7 APAAP staining of mesothelioma cells in a pleural effusion smear with antibody E29. This staining was performed on a smear which had been previously stained conventionally with May-Grunwald Giemsa, and mounted for microscopy. In order to demonstrate EMA the coverslip was removed with xylol, and the slide then transferred via alcohol to buffer, before applying antibody E29 and the reagents for APAAP immuno-alkaline phosphatase labelling.
.40... .I 6 that overall such cases are rare, and they are usually clearly identifiable on purely morphological grounds as being lymphoid in nature. This is reflected in the fact that in a recent study of 120 tumour biopsies which required immunohistological analysis to establish their cellular origin, reactivity of lymphomas with antibody E29 was only rarely seen, and did not pose any major practical obstacle to diagnosis (Gatter et al., 1985) . It may be noted, however, in this context that the risk of misdiagnosis in such cases can be further reduced by the inclusion of an anti-cytokeratin in the monoclonal antibody panel.
The antibodies described in the present paper show similarities to the two monoclonal antibodies against defatted preparations of human cream (designated HMFG-1 and HMFG-2) reported by Taylor-Papadimitriou et al. (1983) and by Arklie et al. (1981) , since they react with antigenic material in human milk which is of high mol. wt and give similar immunocytochemical labelling reactions (Gatter et al., 1982) . However it should be noted that differences can be detected between antibodies HMFG1 and HMFG2, when their reactivity patterns are assessed by a variety of techniques (immunoblotting, immunohistology, binding to cell lines and lectin blocking - Burchell et al., 1983 , Taylor-Papadimitriou et al., 1985 . Antibody E29 may not be identical in specificity to either of these reagents, and indeed the direct comparison of immunohistological reactions reported in the accompanying paper indicate that antibody E29 gives cleaner labelling of human tissues than antibody HMFG2. Foster et al. (1982) have reported the production of monoclonal antibodies (designated M8 and M18) against human milk fat globules which also react with high mol. wt molecules of heterogenous size, and show close similarities in their immunohistochemical reactions to antibody E29. More recently Ellis et al. (1984) have reported a monoclonal antibody (NCRC-l 1) which was raised against human breast carcinoma cells and which gives immunohistological labelling reactions very similar to those of E29. Antibody NCRC-1 1 was also able to partially inhibit binding of one of the anti-EMA antibodies reported by .
It is evident from the results reported in this paper that antibody E29 is of considerable practical diagnostic value because of the clarity with which it labels cells of epithelial origin in routine paraffin embedded tissue and in air dried routine cytological smears. It reacts with all mammary carcinomas against which it has been tested, and has been shown to be capable of detecting micrometastases of this tumour in 15% of axillary lymph nodes from breast carcinoma patients in whom tumour is undetectable on routine histological examination (Wells et al., 1984) . Furthermore antibody E29 may be used to detect metastatic carcinoma cells in routinely prepared smears of bone marrow aspirates (Ghosh et al., 1985) . The antibody is of particular value when used in conjunction with monoclonal antibodies which react with leucocyte-associated antigens, since this combination of antibodies enables the majority of anaplastic tumours of uncertain type to be reliably classified as either lymphoma or carcinoma (Gatter et al., 1984a (Gatter et al., , b, 1985 .
